In vitro and in vivo evaluation of [18F]F-GAZ, a novel oxygen-mimetic azomycin-glucose conjugate, for imaging hypoxic tumor

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 8, 2012, Pages 473-480

  Wuest, Melinda ^a   Kumar, Piyush ^a   Wang, Monica ^a   Yang, Jennifer ^a   Jans, Hans Soenke ^a   Wiebe, Leonard I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

azomycin; EMT 6; F GAZ; GLUT; oxygen mimetic radiosensitizer; PET; Tumor hypoxia

Indexed keywords

2 NITROIMIDAZOLE DERIVATIVE; N (2 FLUORO 3 (6 O GLUCOSYL)PROPYLAZOMYCIN F 18; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SYNTHESIS; FEMALE; GLUCOSE TRANSPORT; HYPOXIA; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOPHILICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; TUMOR XENOGRAFT;

ANIMALS; BIOMIMETIC MATERIALS; CELL HYPOXIA; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NITROIMIDAZOLES; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84867516116     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.1148     Document Type: Article

References (44)

1. Stahl A, Wieder H, Piert M, et al. Positron emission tomography as a tool for translational research in oncology. Mol Imaging Biol 2004;6:214.
2. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005;43:169.
3. Vaupel P. Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. Oncologist 2008;13(S3):21.
4. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: Cancer cells compress intratumoural vessels. Nature 2004;427:695.
5. Raghunand N, Gatenby RA, Gillies RJ. Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 2003;76:S11.
6. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 2001;18:243.
7. Sannazzari GL, Ricardi U, Filippi AR. Hypoxia and tumor response to irradiation. Rays 2002;27:175.
8. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumour oxygenation in 397 head and neck tumours after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18.
9. Imam SK. Review of positron emission tomography tracers for imaging of tumor hypoxia. Cancer Biother Radiopharm 2010;25:365.
10. Mees G, Dierckx R, Vangestel C, et al. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009;36:1674.
11. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699.
12. Adams GE, Clarke ED, Flockhart IR, et al. Structure-activity relationships in the development of hypoxic cell radiosensitizers I. Sensitization efficiency. Int J Radiat Biol 1979;35:133.
13. Brown JM, Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 1980;82:171.
14. Nagasawa H, Uto Y, Kirk KL, et al. Design of hypoxia-targeting drugs as new cancer chemotherapeutics. Biol Pharm Bull 2006;29:2335.
15. Wiebe LI, McEwan AJB. Scintigraphic imaging of focal hypoxic tissue: Development and clinical applications of 123I-IAZA. Brazilian Arch Biol Technol 2002;45:S89.
16. Arabi M, Piert M. Hypoxia PET/CT imaging: Implications for radiation oncology. Q J Nucl Med Mol Imaging 2010;54:500.
17. Grierson JR, Link JM, Mathis CA, et al. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343.
18. Mannan RH, Somayaji VV, Lee J, et al. Radioiodinated 1-(5-iodo-5-deoxy-b- D-arabinofuranosyl)-2-nitroimidazole (Iodoazomycin Arabinoside: IAZA), a novel marker of tissue hypoxia. J Nucl Med 1991;32:1764.
19. Kumar P, Stypinski D, Xia H, et al. Fluoroazomycin arabinoside (FAZA): Synthesis, 2H and 3H-labeling and preliminary biological evaluation of a novel 2-nitromidazole marker for tissue hypoxia. J Labelled Cpd Radiopharm 1999;42:3.
20. Postema EJ, McEwan AJ, Riauka TA, et al. Hypoxia imaging using 1-a-D-(5-deoxy-5-[18F]-fluoroarabino-furanosyl)-2-nitroimidazole (18F-FAZA): The initial results of a Phase I/II study. Eur J Nucl Med Mol Imaging 2009;36:1565.
21. Patt M, Sorger D, Scheunemann M, et al. Adduct of 2-[18F]FDG and 2-nitroimidazole as a putative radiotracer for the detection of hypoxia with PET: Synthesis, in vitro- and in vivo-characterization. Appl Radiat Isot 2002;57:705.
22. Bormans GM, Van Oosterwyck G, De Groot TJ, et al. Synthesis and biologic evaluation of 11C-methyl-D-glucoside, a tracer of the sodium-dependent glucose transporters. J Nucl Med 2003;44:1075.
23. De Groot TJ, Veyhl M, Terwinghe C, et al. Synthesis of 18Ffluoroalkyl-ß-D-glucosides and their evaluation as tracers for sodium-dependent glucose transporters. J Nucl Med 2003;44:1973.
24. Landau BR, Spring-Robinson CL, Muzic RF, et al. 6-Fluoro-6-deoxy-D- glucose as a tracer for glucose transport. Am J Physiol Endocrinol Metab 2007;293:E237.
25. Spring-Robinson CL, Chandramouli V, Schumann WC, et al. Uptake of 18F-labeled 6-fluoro-6-deoxy-D-glucose by skeletal muscle is responsive to insulin stimulation. J Nucl Med 2009;50:912.
26. Henry C, Koumanov F, Ghezzi C, et al. [123I]-6-deoxy-6-iodo-D-glucose (6DIG): A potential tracer for glucose transport. Nucl Med Biol 1997;24:527.
27. Perret P, Ghezzi C, Ogier L, et al. Biological studies of radiolabeled glucose analogues iodinated in positions 3,4 or 6. Nucl Med Biol 2004;31:241.
28. Barros LF, Bittner CX, Loaiza A, et al. Kinetic validation of 6-NBDG as a probe for the glucose transporter GLUT1 in astrocytes. J Neurochem 2009;109:94.
29. Wiebe LI, Kumar P, Zheng W. Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof. International patent, WO 2010/073126, 1 July 2010.
30. Kumar P, Shustov G, Liang H, et al. Design, synthesis and preliminary biological evaluation of 6-O-glucose-azomycin adducts for diagnosis and therapy of hypoxic tumors. J Med Chem 2012[Epub ahead of print].
31. Bouvet VR, Wuest M, Wiebe LI, et al. Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-a-d-arabinofuranosyl)-2-nitroimidazole using microfluidic technology. Nucl Med Biol 2011;38:235.
32. Nakae T, Uto Y, Tanaka M, et al. Design, synthesis, and radiosensitizing activities of sugar-hybrid hypoxic cell radiosensitizers. Bioorg Med Chem 2008;16:675.
33. Bayly SR, King RC, Honess DJ, et al. In vitro and in vivo evaluations of a hydrophylic 64Cu-bis(thiosemicarbazonato)-glucose conju-gate for hypoxia imaging. J Nucl Med 2008; 49:1862.
34. Zhang M, Zhang Z, Blessington D, et al. Pyropheophorbide 2-deoxyglucosamide: A new photosensitizer targeting glucose transporters. Bioconjug Chem 2003;14:709.
35. Malik N, Lin X, Lö ffler D, et al. Synthesis of O-[2-[18F]fluoro-3- (2-nitro-1H-imidazole-1-yl) propyl]tyrosine ([18F]FNT]) as a new class of tracer for imaging hypoxia. J Radioanal Nucl Chem 2012;292:1025.
36. Loike JD, Cao L, Brett J, et al. Hypoxia induces glucose transporter expression in endothelial cells. Am J Physiol 1992;263:C326.
37. Urtasun RC, Chapman JD, Feldstein ML, et al. Peripheral neuropathy related to misonidazole: Incidence and pathology. Br J Cancer Suppl 1978;3:271.
38. Wasserman TH, Phillips TL, Johnson RJ, et al. Initial United States clinical and pharmacologie evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 1979;5:775.
39. Coleman CN, Halsey J, Cox RS, et al. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. Cancer Res 1987;47:319.
40. Suehiro M, Burgman P, Carlin S, et al. Radiosynthesis of [131I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker? Nucl Med Biol 2009;36:477.
41. Procissi D, Claus F, Burgman P, et al. In vivo 19F magnetic resonance spectroscopy and chemical shift if tri-fluoronitroimidaziole as a potential hypoxia reporter in solid tumors. Clin Cancer Res 2007;13:3738.
42. Schibli R, Dumas C, Petrig J, et al. Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against Glut 1 and hexokinase. Bioconjug Chem 2005;16:105.
43. Wuest M, Trayner BJ, Grant TN, et al. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-d-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nucl Med Biol 2011;38:461.
44. Kobayashia M, Shikanoc N, Nishiid R, et al. Comparison of the transcellular transport of FDG and D-glucose by the kidney epithelial cell line, LLC-PK1. Nucl Med Commun 2010;31:141.